CA2024968A1 - Medicament contre la demence - Google Patents

Medicament contre la demence

Info

Publication number
CA2024968A1
CA2024968A1 CA002024968A CA2024968A CA2024968A1 CA 2024968 A1 CA2024968 A1 CA 2024968A1 CA 002024968 A CA002024968 A CA 002024968A CA 2024968 A CA2024968 A CA 2024968A CA 2024968 A1 CA2024968 A1 CA 2024968A1
Authority
CA
Canada
Prior art keywords
rolipram
dementia
session
rats
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002024968A
Other languages
English (en)
Inventor
Taiichiro Imanishi
Yasuyuki Ichimaru
Aiko Sawa
Fukio Konno
Helmut Wachtel
Showa Ueki
Michihiro Fujiwara
Tsuneyuki Yamamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2024968A1 publication Critical patent/CA2024968A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
CA002024968A 1989-12-11 1990-09-10 Medicament contre la demence Abandoned CA2024968A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP1318818A JP2578001B2 (ja) 1989-12-11 1989-12-11 抗痴呆薬
JP1-318818 1989-12-11

Publications (1)

Publication Number Publication Date
CA2024968A1 true CA2024968A1 (fr) 1991-06-12

Family

ID=18103291

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002024968A Abandoned CA2024968A1 (fr) 1989-12-11 1990-09-10 Medicament contre la demence

Country Status (4)

Country Link
US (1) US5059612A (fr)
EP (1) EP0432856A3 (fr)
JP (1) JP2578001B2 (fr)
CA (1) CA2024968A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0542795T5 (da) * 1990-08-03 1998-09-07 Smithkline Beecham Corp TNF-inhibitorer
AU2224195A (en) * 1994-04-15 1995-11-10 Masaomi Iyo Medicinal composition for treating tardive dyskinesia and utilization thereof
US6096302A (en) * 1996-10-04 2000-08-01 The Trustees Of Columbia University In The City Of New York Assay for the measurement of neuronal degradation and uses thereof
US9931318B2 (en) * 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US8153646B2 (en) 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
EP2316531A1 (fr) * 2000-08-10 2011-05-04 Cold Spring Harbor Laboratory Apprentissage cognitif amélioré
EP1389468A4 (fr) 2001-05-23 2007-01-10 Tanabe Seiyaku Co Compositions favorisant la gu rison d'une fracture osseuse
CN1537018A (zh) 2001-05-23 2004-10-13 田边制药株式会社 一种用于软骨疾病再生治疗的组合物
US6825229B2 (en) 2002-03-07 2004-11-30 Blanchette Rockefeller Neurosciences Institute Methods for Alzheimer's Disease treatment and cognitive enhancement
US20050065205A1 (en) 2002-03-07 2005-03-24 Daniel Alkon Methods for Alzheimer's disease treatment and cognitive enhance
TW201206425A (en) 2004-05-18 2012-02-16 Brni Neurosciences Inst Treatment of depressive disorders
US20070054890A1 (en) 2005-07-29 2007-03-08 Alkon Daniel L Protein synthesis required for long-term memory is induced by PKC activation on days preceding associative learning
US7858611B2 (en) 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
ES2412481T3 (es) * 2006-05-19 2013-07-11 Dart Neuroscience Llc Inhibidores de la fosfodiesterasa 4 para la rehabilitación motora
EP3332797A3 (fr) 2007-02-09 2018-08-01 Blanchette Rockefeller Neurosciences Institute Effets thérapeutiques des bryostatines, bryologues et autres substances apparentées sur les troubles de la mémoire et les lésions cérébrales suite à un traumatisme crânien
CN107648224A (zh) * 2017-10-31 2018-02-02 泰州中国医药城中医药研究院 一种治疗和预防心力衰竭药物及其在制药中的应用
WO2020102374A1 (fr) * 2018-11-14 2020-05-22 The Board Of Trustees Of The Leland Stanford Junior University Ciblage de complexes makap-pde4d3 dans une maladie neurodégénérative

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
DE2413935A1 (de) * 1974-03-20 1975-10-16 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone
DE2541855A1 (de) * 1975-09-18 1977-03-31 Schering Ag 4-(polyalkoxy-phenyl)-2-pyrrolidone ii
DE3104435A1 (de) * 1981-02-03 1982-11-11 Schering Ag, 1000 Berlin Und 4619 Bergkamen Wirkstoffkombination

Also Published As

Publication number Publication date
JP2578001B2 (ja) 1997-02-05
EP0432856A2 (fr) 1991-06-19
EP0432856A3 (en) 1991-11-27
US5059612A (en) 1991-10-22
JPH03181418A (ja) 1991-08-07

Similar Documents

Publication Publication Date Title
CA2024968A1 (fr) Medicament contre la demence
US12534438B2 (en) Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof
DE3636123C2 (fr)
PT89109B (pt) Metodo para melhorar a funcao cognitiva por administracao de d-ciclosserina e suas pro-drogas
Roth et al. Evidence that central nervous system depression by 1, 4-butanediol is mediated through a metabolite, gamma-hydroxybutyrate
US4788179A (en) Method of treating amyotrophic lateral sclerosis with dipeptide derivatives and pharmaceutical compositions for use therein
US5510381A (en) Method of treatment of mania and bipolar disorder
DE69104314T2 (de) Verwendung von 1-[3-(Dimethylamino)propyl]-1-phenylphthalenen zur Behandlung zerebrovaskulärer Störungen.
EP0607775A2 (fr) Utilisation de leflunomid pour inhiber interleukin 1 bêta
HU201672B (en) Process for producing pharmaceutical compositions comprising podophyllotoxin
US5962523A (en) Methods of using butyric acid derivatives to protect against hair loss
JPS6210206B2 (fr)
US5011841A (en) Treatment of depression
Chapman et al. Antagonism of some toxic effects of dextropropoxyphene by nalorphine
Hosein et al. Intramuscular/oral lorazepam in acute alcohol withdrawal and incipient delirium tremens
DE68915595T2 (de) Verwendung von Isoxazolinonen als cerebro-aktive Medikamente.
DE69028603T2 (de) Arzneimittel für bessere gehirnwirkung
AU5456899A (en) Medicinal product and method for treatment and prevention of dyskinesia
JP2003530350A (ja) 外傷性脳損傷及びその他のニューロン障害治療用医薬
DE69221649T2 (de) Lacidipin zur Behandlung der Arteriosklerosis
DE3887426T2 (de) Eperisone als Hypotonikum.
Finer Diphenylhydantoin for treatment of alcohol withdrawal syndromes
DE3821392A1 (de) Neue pharmazeutische verwendung von 2-phenyl-1,2-benzisoselenazol-3(2h)-on (ebselen)
KR960014873B1 (ko) 제피론을 함유하는 공황(恐慌)장애 경감용 약학 조성물
DE3816937C2 (fr)

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued